Abstract |
The presence of comutations (co-mut+) in DNA damage response and repair (DDR) pathways was associated with improved survival for immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). However, it remains unknown whether co-mut+ status could be a predictive biomarker for immunotherapy. We aimed to explore the predictive role of co-mut+ status in the efficacy of ICIs. A total of 853 NSCLC patients from OAK and POPLAR trials were included in the analyses for the relationship between co-mut status and clinical outcomes with atezolizumab treatment. In co-mut+ NSCLC patients, significantly prolonged progression-free survival (PFS) (p = 0.004) and overall survival (OS) (p < 0.001) were observed in atezolizumab over docetaxel. The interaction between co-mut status and treatment was significant for PFS (p for interaction = 0.010) and OS (p for interaction = 0.017). In patients with negative or low programmed death receptor- ligand 1 expression, co-mut+ status still predicted improved clinical outcomes from atezolizumab therapy. These findings suggested that co-mut status may be a promising predictor of ICI therapy in NSCLC.
|
Authors | Anning Xiong, Wei Nie, Yan Zhou, Changhui Li, Kai Gu, Ding Zhang, Shiqing Chen, Fengcai Wen, Hua Zhong, Baohui Han, Xueyan Zhang |
Journal | Frontiers in immunology
(Front Immunol)
Vol. 12
Pg. 708558
( 2021)
ISSN: 1664-3224 [Electronic] Switzerland |
PMID | 34630387
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Xiong, Nie, Zhou, Li, Gu, Zhang, Chen, Wen, Zhong, Han and Zhang. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- atezolizumab
|
Topics |
- Aged
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics)
- DNA Damage
(genetics)
- DNA Repair
(genetics)
- Female
- Humans
- Lung Neoplasms
(drug therapy, genetics)
- Male
- Middle Aged
- Mutation
- Progression-Free Survival
- Treatment Outcome
|